Tetrous, Inc.

Media Contact:

Bradley Patt, PhD
Tetrous, Inc.
818-645-4081
bpatt@tetrous.com

Product Information:

John Bojanowski
Tetrous, Inc.
978-809-0374
jbojanowski@tetrous.com

TETROUS ANNOUNCES FIRST SURGICAL PROCEDURES USING ENFIX TAC™ DEMINERALIZED BONE FIBER IMPLANTS TO ENHANCE ENTHESIS HEALING IN ROTATOR CUFF REPAIR

Los Angeles, CA, MAY 8, 2024 – TETROUS, INC., a leading regenerative medicine company today announced that it has completed the first surgical cases using EnFix TAC™, its latest product that expands its line of EnFix™ implants to cover every surgical technique for rotator cuff repair.

The EnFix product line is specifically designed to address Enthesis Failure Syndrome.

The EnFix technology utilizes proprietary demineralized cortical bone fibers to yield an osteoinductive and osteoconductive implant that promotes optimal biologic healing at the bone-to-tendon interface, resulting in reformation of the enthesis. With strong pre-clinical data and promising early clinical results showing healing at the bone-to-tendon interface, there is growing evidence supporting the applicability of the EnFix technology to address the unmet need for technology that can improve on the weak repair at the enthesis that is driving the high surgical failure rates in rotator cuff repairs.

The EnFix TAC is the second offering in the EnFix family of implants and is available in two configurations, TAC-O and TAC-T, to accommodate the varied availability of bony real estate based on the size of the rotator cuff tear. While the EnFix RC™ is designed to be used with suture anchors, the EnFix TAC options are specifically designed to deliver the same enthesis healing properties in a graft that is intended for use independent of a suture anchor or with all-suture anchors.

EnFix TAC

Nikhil Verma, MD, Professor and Director, Sports Medicine and Shoulder, Midwest Orthopedics at Rush, Head Team Physician, Chicago White Sox, who performed the first surgeries with the EnFix TAC said, “When it comes to surgical outcomes in rotator cuff repair, enthesis healing is one of the most critical factors. The EnFix implants address this crucial need with minimal disruption to the surgical procedure”. He continued, “I believe these products will have a transformative impact on surgical protocols in rotator cuff repair”.

Since June 2023, in the initial commercial release of the EnFix implants, more than 400 grafts have been implanted in over 200 surgical cases in the US and Australia.

###

About Tetrous, Inc.

Founded in 2019, Tetrous, Inc. utilizes next generation advanced technologies for enthesis repair in sports medicine applications. The first offerings in the EnFix family of products are EnFix RC and EnFix TAC for rotator cuff repair. Tetrous was conceived from technology developed for spine surgery. The Company is employing and expanding the technology for novel applications in sports medicine. Its core technology has been used in over 100,000 implants in spine applications. The demineralized bone fiber technology used in Tetrous products is licensed exclusively for use in sports medicine from TheraCell, an ISTO Biologics Company.  EnFix™, EnFix RC™ and EnFix TAC™ are trademarks of Tetrous, Inc.

For  more information visit www.tetrous.com and follow us on LinkedIn (www.linkedin.com/company/tetrous). 

About Australian Biotechnologies

Australian Biotechnologies manufactures and distributes life enhancing allograft tissue products for the Australian community. The business was founded in 2000 and is located in Frenchs Forest, New South Wales, Australia. With world class processing facilities, specially trained technical staff and strict quality procedures, the company is the first privately owned and operated tissue-processing facility in Australia. 

Bradley E. Patt, PhD

Dr. Patt is cofounder chairman of Tetrous.

Brad has over 40 years experience as an entrepreneur and executive manager. He has led several enterprises from start-up phase through rapid growth and merger and acquisitions.

Brad founded several high tech ventures since 1997. He is currently co-founder chairman and CEO of TheraCell and DermOQ. Previously he was co-founder, CEO and Chairman of Gamma Medica, Inc. Brad built Gamma to market leadership position in pre­clinical CT, PET, SPECT imaging and is inventor and developer of Molecular Breast Imaging for detecting otherwise occult breast cancer in dense­breasted women.

Brad is currently co­founder and Chairman of DermOQ, Inc., an oxygen skin care company; EVO Worldwide, Inc. and spin off Smart Breast Corp., medical diagnostic imaging systems companies; and Hyvida Brands, a functional beverage startup. He is a director of High Beauty a cannabis cosmetic company. Brad also founded and is a Director of Thrive Outside the Box, a nonprofit organization that identifies and develops areas of talent in individuals on the autistic spectrum.

Brad is an internationally recognized authority in the field of medical imaging with over one hundred scientific papers and presentations, several book chapters, and over 20 patents. He has been an invited speaker at several international conferences. He has held elected positions on the IEEE Nuclear Medicine Instrumentation Steering Committee (NMISC) and the IEEE Radiation Instrumentation Steering Committee (RISC), and was appointed to the Program Committee of the SPIE Medical applications of Penetrating Radiation, acting as Chairman of the Penetrating Radiation Work Group for 2003 and 2004. Dr. Patt is a consultant to the National Institutes of Health and the recipient of over $15 million dollars of grant awards as Principal Investigator from the National Institutes of Health, The United States Department of Energy and NASA.

Bradley E. Patt, PhD

Dr. Patt is cofounder chairman of Tetrous. Brad has over 40 years experience as an entrepreneur and executive manager. He has led several enterprises from start-up phase through rapid growth and merger and acquisitions. Brad founded several high tech ventures since 1997. He is currently co-founder chairman and CEO of TheraCell and DermOQ. Previously he was co-founder, CEO and Chairman of Gamma Medica, Inc. Brad built Gamma to market leadership position in pre­clinical CT, PET, SPECT imaging and is inventor and developer of Molecular Breast Imaging for detecting otherwise occult breast cancer in dense­breasted women. Brad is currently co­founder and Chairman of DermOQ, Inc., an oxygen skin care company; EVO Worldwide, Inc. and spin off Smart Breast Corp., medical diagnostic imaging systems companies; and Hyvida Brands, a functional beverage startup. He is a director of High Beauty a cannabis cosmetic company. Brad also founded and is a Director of Thrive Outside the Box, a nonprofit organization that identifies and develops areas of talent in individuals on the autistic spectrum. Brad is an internationally recognized authority in the field of medical imaging with over one hundred scientific papers and presentations, several book chapters, and over 20 patents. He has been an invited speaker at several international conferences. He has held elected positions on the IEEE Nuclear Medicine Instrumentation Steering Committee (NMISC) and the IEEE Radiation Instrumentation Steering Committee (RISC), and was appointed to the Program Committee of the SPIE Medical applications of Penetrating Radiation, acting as Chairman of the Penetrating Radiation Work Group for 2003 and 2004. Dr. Patt is a consultant to the National Institutes of Health and the recipient of over $15 million dollars of grant awards as Principal Investigator from the National Institutes of Health, The United States Department of Energy and NASA.